Year: 2025
Type: article
Study design: Clinical Trial
Abstract: PURPOSE: Owing to uncertainty on best management, a subset of patients with small renal masses suspicious for kidney cancer experience elevated decisional conflict. We hypothesize that pathologic information from renal mass biopsy (RMB) may improve patient decision-making. In this study, we evaluate the impact of RMB on decisional conflict for patients with clinical T1 renal masses. MATERIALS AND METHODS: A comparative, nonrandomized clinical trial was performed at a large tertiary cancer center. Patients with new clinical T1 renal masses were self-assigned to standard-of-care biopsy. We used difference-in-difference (DiD) analyses to assess change in decisional conflict scale by receipt of RMB. RESULTS: = .20). Among subgroups, DiD by biopsy was large for total decisional conflict score in patients who did not see an outside urologist (-6.22) and patients reporting lower communication scores (-8.24). CONCLUSIONS: Though RMB did not significantly decrease decisional conflict in all patients, biopsy reduced decisional conflict in certain patient subsets, demonstrating the importance of further investigating how to better support patients after renal mass diagnosis.
Source: The Journal of Urology
Authors: Kathryn H. Gessner, Allison M. Deal, Amir Feinberg, Shannon Myers, Katherine Poulos, Hillary Heiling, Sara Wobker, Pranav Akella, Marc A. Bjurlin, Clayton Commander, Matthew I. Milowsky, Matthew E. Nielsen, Mathew Raynor, Angela B. Smith, Eric Wallen, David C. Johnson, William Y. Kim, Hung-Jui Tan
Language: English
Subfield: General Health Professions
Field: Health Professions
Domain: Health Sciences
Open Access status: green
Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Gilead Sciences, Patient-Centered Outcomes Research Institute, Intuitive Surgical, Accuray, Mirati Therapeutics, UroGen Pharma, National Institutes of Health, Agency for Healthcare Research and Quality, Genentech, National Cancer Institute, National Center for Advancing Translational Sciences, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
OpenAlex ID: W4415633373
FWCI:
Cites:
Cited by:
Related to:
